Topics

Provention Bio’s Phase 2a Trial of its Oral CSF-1R Inhibitor Fails to Meet Primary Endpoint in Patients with Moderate to Severe Crohn’s Disease

11:02 EDT 22 Oct 2019 | Speciality Pharma Journal

OLDWICK, N.J., Oct. 22, 2019 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced top-line results from its randomized, placebo-controlled Phase 2a PRINCE clinical trial evaluating twice-daily PRV-6527, an oral Colony Stimulating Factor-1 Receptor (CSF-1R) small molecule inhibitor. The PRINCE study enrolled 93 …

Original Article: Provention Bio’s Phase 2a Trial of its Oral CSF-1R Inhibitor Fails to Meet Primary Endpoint in Patients with Moderate to Severe Crohn’s Disease

NEXT ARTICLE

More From BioPortfolio on "Provention Bio’s Phase 2a Trial of its Oral CSF-1R Inhibitor Fails to Meet Primary Endpoint in Patients with Moderate to Severe Crohn’s Disease"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...